Making complex and innovative products at scale, the next frontier, say pharma chiefs

Indian pharmaceutical leaders recognize the critical importance of leveraging artificial intelligence (AI) and strategic collaborations to advance the production of complex and innovative drugs at scale. Amid ongoing geopolitical challenges impacting global supply chains, executives from major companies such as Aurobindo Pharma, Lupin, Sun Pharmaceuticals, and Zydus Lifesciences have emphasized the need to go beyond traditional generics manufacturing and evolve towards more innovative, science-driven drug development and manufacturing models. AI technologies are being increasingly adopted to accelerate drug discovery and optimize manufacturing processes, enabling Indian pharma to meet growing global demand for new and complex therapies efficiently. This digital transformation aligns with India’s broader opportunity to shift from cost-led production to integrated platforms that combine novel science, digital intelligence, and modular manufacturing capabilities. Such advances not only enhance India’s competitive edge but also support global healthcare innovation by delivering high-quality, complex pharmaceutical products at scale. The focus on system-led execution—integrating discovery, AI-driven analytics, and manufacturing excellence—is pivotal as Indian companies seek to assert leadership amid geopolitical uncertainties and rising demand for specialized medicines. This strategic embrace of AI and collaboration marks an essential evolution in Indian pharma’s global role, driving sustainable growth and innovation within a rapidly transforming industry landscape.